

ŚWIERCZ, Maciej, MARKOWIAK, Szymon, WARDESZKIEWICZ, Marta, JABŁOŃSKA, Wiktoria, KASPRZAK, Amelia, TRUCHTA, Monika, MAŃKOWSKA, Aleksandra, KOLANO, Agata and PEJAS, Anna. Anesthetic Strategies in Cerebral Edema: Navigating Neurological Challenges Amid Trauma, Tumors and Therapeutic Advances. Journal of Education, Health and Sport. 2024;53:75-90. eISSN 2391-8306. <https://dx.doi.org/10.12775/JEHS.2024.53.006>
<https://apcz.umk.pl/JEHS/article/view/47802>
<https://zenodo.org/records/10521456>

The journal has had 40 points in Ministry of Education and Science of Poland parametric evaluation. Annex to the announcement of the Minister of Education and Science of 05.01.2024 No. 32318. Has a Journal's Unique Identifier: 201159. Scientific disciplines assigned: Physical culture sciences (Field of medical and health sciences); Health Sciences (Field of medical and health sciences). Punkty Ministerialne z 2019 - aktualny rok 40 punktów. Załącznik do komunikatu Ministra Edukacji i Nauki z dnia 05.01.2024 Lp. 32318. Posiada Unikatowy Identyfikator Czasopisma: 201159. Przypisane dyscypliny naukowe: Nauki o kulturze fizycznej (Dziedzina nauk medycznych i nauk o zdrowiu); Nauki o zdrowiu (Dziedzina nauk medycznych i nauk o zdrowiu).

© The Authors 2024.

This article is published with open access at Licensee Open Journal Systems of Nicolaus Copernicus University in Torun, Poland

Open Access. This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author (s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non commercial license Share alike. (<http://creativecommons.org/licenses/by-nc-sa/4.0/>) which permits unrestricted, non commercial use, distribution and reproduction in any medium, provided the work is properly cited.

The authors declare that there is no conflict of interests regarding the publication of this paper.

Received: 04.01.2024. Revised: 06.01.2024. Accepted: 16.01.2024. Published: 17.01.2024.

Anesthetic Strategies in Cerebral Edema: Navigating Neurological Challenges Amid Trauma, Tumors and Therapeutic Advances

Maciej Świercz

Karol Jonscher Municipal Medical Center located at 14 Milionowa St., 93-113 Lodz

ORCID 0009-0008-6676-6988

<https://orcid.org/0009-0008-6676-6988>

E-mail: maciej.swiercz7@gmail.com

Szymon Markowiak

Norbert Barlicki Memorial Teaching Hospital No. 1 of the Medical University of Lodz
located at 22 Kopcińskiego St., 90-153 Lodz

ORCID 0009-0006-7677-6739

<https://orcid.org/0009-0006-7677-6739>

E-mail: markowiakszymon@gmail.com

Marta Wardęszkiewicz

Military Medical Academy Memorial Teaching Hospital of the Medical University of Lodz –
Central Veteran Hospital located at 113 Żeromskiego St., 90-549 Lodz

ORCID 0009-0001-6415-5963

<https://orcid.org/0009-0001-6415-5963>

E-mail: marta.wardeszkiwicz@gmail.com

Wiktoria Jabłońska

Military Medical Academy Memorial Teaching Hospital of the Medical University of Lodz –
Central Veteran Hospital located at 113 Żeromskiego St., 90-549 Lodz

ORCID 0009-0006-2659-5649

<https://orcid.org/0009-0006-2659-5649>

E-mail: wijablonska@gmail.com

Amelia Kasprzak

Military Medical Academy Memorial Teaching Hospital of the Medical University of Lodz –
Central Veteran Hospital located at 113 Żeromskiego St., 90-549 Lodz

ORCID 0009-0008-2123-1314

<https://orcid.org/0009-0008-2123-1314>

E-mail: amelia.k.kasprzak@gmail.com

Monika Truchta

Central Teaching Hospital of the Medical University of Lodz located at ul. Pomorska 251, 92-
213 Lodz

ORCID 0009-0000-8177-9164

<https://orcid.org/0009-0000-8177-9164>

E-mail: monikatruchta@gmail.com

Aleksandra Mańkowska

Central Teaching Hospital of the Medical University of Lodz located at ul. Pomorska 251, 92-213 Lodz

ORCID 0009-0009-3926-4920

<https://orcid.org/0009-0009-3926-4920>

E-mail: mankowskaa96@gmail.com

Agata Kolano

Military Medical Academy Memorial Teaching Hospital of the Medical University of Lodz – Central Veteran Hospital located at 113 Żeromskiego St., 90-549 Lodz

ORCID 0009-0003-6418-2130

<https://orcid.org/0009-0003-6418-2130>

E-mail: agathe.kolano@gmail.com

Anna Pejas

Independent Public Healthcare Center in Mława located at 1 A. Dobrskiej St., 06-500 Mława.

ORCID 0009-0008-1469-4994

<https://orcid.org/0009-0008-1469-4994>

E-mail: annapejas@gmail.com

ABSTRACT

Cerebral edema, characterized by abnormal fluid accumulation in brain tissue leading to increased intracranial pressure, poses significant challenges for anesthesiologists. This review delves into the pathophysiology, clinical manifestations, diagnostic approaches, pharmacological strategies, and anesthesiological considerations associated with cerebral edema. Disruptions in the blood-brain barrier, alterations in cerebral blood flow, cellular swelling, and aquaporin dysregulation contribute to the complexity of cerebral edema. Clinical presentations vary, encompassing cognitive changes, seizures, and neurological deficits. Accurate diagnosis relies on clinical assessments and neuroimaging, with MRI and CT scans playing pivotal roles. Pharmacological interventions, including osmotic agents, corticosteroids, diuretics, and barbiturates, target specific causes and symptoms. Anesthesiological challenges encompass ICP monitoring, choice of anesthetic agents, maintenance of cerebral perfusion, fluid management, temperature control, and collaboration with neurosurgical teams. This multidisciplinary approach ensures optimal patient care and emphasizes ongoing research collaboration for refining therapeutic strategies. This comprehensive review provides valuable insights for clinicians managing cerebral edema, offering a roadmap for tailored interventions and highlighting the need for continued advancements in understanding and treating this critical condition.

Material and method:

The literature review applied standard criteria and focused on PubMed articles using keywords: cerebral edema, pathophysiology, aquaporin, blood-brain barrier, anesthesiology, cerebral edema treatment, corticosteroids

Key Words: Cerebral edema, brain swelling, intracranial pressure, brain hemorrhage, brain tumor

INTRODUCTION

Cerebral edema is a term used for the abnormal accumulation of fluid within brain tissue, which inevitably leads to an increase in intracranial pressure (ICP). It can be caused by various medical conditions, such as traumatic brain injury, ischemic stroke, infectious diseases, and other neurological disorders. Commonly known as „brain swelling” poses many difficulties in treatment especially for anesthesiologists, who need to consider all kinds of medical treatment and anesthesia, which may differ from standard, daily procedures. [3,4,5]

PATHOPHYSIOLOGY

Cerebral edema results from complex physiological processes that disrupt the balance of fluid within the brain. When considering the issue of cerebral edema, it is important to list the factors that can cause swelling. These include disorders of a vascular nature (strokes), craniocerebral trauma (including hematomas), tumors, and inflammatory conditions (encephalitis, brain abscess). [1] Understanding those pathomechanisms is crucial for precise therapeutic interventions. In this section, we will focus on the most common causes in clinical practice.

Blood–Brain Barrier (BBB) Disruption:

The term blood-brain barrier refers to a complex of cells that separates the brain interstitium from the luminal contents of the cerebral vasculature. [2] In conditions such as brain hemorrhage or inflammation blood-brain barrier might get damaged, which causes disruption that allows plasma components to enter the brain. Plasma filled with ions and proteins triggers an osmotic imbalance in brain tissue, this phenomenon causes brain tissue to expand (because of attracted liquids) and increases pressure in the cranial cavity. [8,14,15]

On the other hand, brain cancers, particularly high-grade gliomas, create an osmotic gradient due to increased cellular density. This gradient promotes water movement into the tumor cells, contributing to vasogenic edema. [21]

In head injuries, traumatic forces can damage cell membranes, leading to the release of intracellular ions. The resulting osmotic imbalance attracts water into the cells, causing cytotoxic edema. [6,13,15,16]

Cerebral Blood Flow Changes:

Brain hemorrhage alters cerebral blood flow dynamics. The accumulation of blood in the intracranial space increases local pressure, influencing regional perfusion and contributing to ischemia and edema in surrounding tissues. [9,15,16]

Inflammation-induced vasodilation and increased blood flow can exacerbate edema. The release of vasoactive substances may lead to a dysregulated autoregulatory response, further impacting cerebral blood flow. [9,15,16]

Cellular Swelling and Cytotoxic Oedema:

Cellular swelling is a hallmark of cytotoxic edema, often observed in ischemic conditions following brain hemorrhage or head injuries. Energy failure during ischemia impairs the function of ion pumps, leading to the accumulation of intracellular sodium and water.

In brain cancers, infiltrating tumor cells may disrupt the normal architecture of the brain, causing cellular swelling and impairing local tissue function. [6,8,11]

Aquaporin Dysregulation:

There are 14 known aquaporin channels, only aquaporin-1, aquaporin-4, aquaporin-9, and aquaporin-11 are expressed in the CNS. Particularly Aquaporin-4 (AQP4), plays a role in the movement of water across cell membranes. Dysregulation of aquaporins can exacerbate cerebral edema. [2,13]

In inflammatory conditions, such as neuromyelitis optica spectrum disorders, autoantibodies against AQP4 may contribute to edema by disrupting the water balance at the cellular level. [13]

CLINICAL MANIFESTATIONS

The clinical manifestations of cerebral edema extend beyond those associated with brain hemorrhage. In cases involving brain cancers, patients may exhibit additional symptoms, including:

Cognitive Changes: Memory loss, personality changes, and cognitive decline may manifest with brain cancers due to their impact on neural networks.

Seizures: Brain cancers, particularly gliomas, can induce seizures as a result of irritation to surrounding brain tissue.

Inflammatory conditions, such as autoimmune encephalitis, may contribute to cerebral edema, leading to symptoms such as:

Psychiatric Symptoms: Changes in behavior, mood, and psychosis can be prominent features of inflammation-induced cerebral edema.

Fever: Inflammatory responses may be accompanied by fever, contributing to the overall clinical picture.

Head injuries, especially traumatic brain injuries (TBIs), present a spectrum of symptoms, including:

Loss of Consciousness: The severity of head injuries may lead to transient or prolonged loss of consciousness.

Amnesia: Memory loss regarding the events surrounding the injury is a common neurological symptom.

Common neurological symptoms associated with cerebral edema and brain hemorrhage include:

Headache: Often severe and persistent, headaches are a common early symptom resulting from increased intracranial pressure.

Nausea and Vomiting: Increased intracranial pressure can stimulate the emetic centers in the brain, leading to nausea and vomiting.

Altered Consciousness: Patients may experience a decline in alertness, ranging from mild confusion to profound lethargy or coma.

Seizures: Cerebral edema, particularly in the context of brain hemorrhage, can irritate the brain tissue, increasing the risk of seizures.

Focal Neurological Deficits: Depending on the location of cerebral edema or the site of hemorrhage, patients may exhibit focal neurological deficits such as weakness, numbness, or visual disturbances.

Impaired Coordination: Cerebral edema affecting the cerebellum may result in impaired coordination and balance.

Changes in Vision: Blurred or double vision can occur due to increased pressure on the optic nerve.

These symptoms, when observed in conjunction with risk factors such as trauma or hypertension, warrant prompt medical evaluation. It is essential to recognize and differentiate these symptoms from other neurological conditions to initiate appropriate diagnostic and therapeutic measures promptly. [1,3,12]

DIAGNOSTIC APPROACHES

Accurate diagnosis of cerebral edema relies on a combination of clinical assessment, neuroimaging studies, and monitoring of intracranial pressure. Imaging modalities such as magnetic resonance imaging (MRI) and computed tomography (CT) scans play a vital role in identifying the presence and extent of cerebral edema. [6,9,12]

PHARMACOLOGICAL STRATEGIES

The pharmacological management of cerebral edema involves the use of various agents to mitigate the underlying causes and alleviate symptoms. The choice of medication depends on the type and severity of cerebral edema. Common pharmacological interventions include:

Osmotic Agents:

The most effective method of reducing cerebral edema by lowering the water content of the extravascular extracellular space is osmotherapy, which aims to reduce the water content within the brain by increasing the blood osmotic gradient.[1,17,19] Two commonly used osmotic agents are mannitol and hypertonic saline.

Mannitol:

Mannitol is a sugar alcohol that acts as an osmotic diuretic. It is administered intravenously to increase serum osmolality, leading to water extraction from brain cells. Mannitol is particularly useful in treating cytotoxic edema associated with conditions like traumatic brain injury and ischemic stroke. Its use is recommended at a dose of 1 g/kg body weight administered every 3-4 hours, with control of plasma osmolality (maintaining osmolality in the range of 300-310 mOsm/l) and control of electrolyte concentrations, as chronic use of mannitol can lead to dyselectrolytaemia. While the use of mannitol is considered the gold standard in the hospital setting, it is not recommended for use in the pre-hospital period. [1,17,19]

Hypertonic Saline:

Hypertonic saline solutions, with concentrations ranging from 3% to 23.4%, can effectively reduce cerebral edema. By increasing serum osmolality, hypertonic saline promotes the movement of water from the intracellular to the extracellular space. This therapy is often utilized in cases where rapid reduction of intracranial pressure is imperative. [17,19]

Corticosteroids:

Corticosteroids, such as dexamethasone, may be considered in specific instances where inflammation plays a significant role in cerebral edema. While their mechanism of action is not entirely clear, corticosteroids are thought to reduce edema by stabilizing the blood-brain barrier and suppressing inflammatory responses. Dexamethasone is usually used in doses of 4-6 mg every 4-6 hours. While corticosteroids are known to have a beneficial therapeutic effect in cases of cerebral edema in brain tumors, in other cases (trauma, strokes) the complications caused by their use, including fatalities, strongly argue against their implementation. [1,18]

Diuretics:

Diuretics, such as furosemide, can be employed to reduce cerebral edema by increasing the excretion of water and electrolytes through urine. Their use is often limited due to concerns about potential dehydration and electrolyte imbalances. Diuretics may be considered in combination with other therapies for managing vasogenic edema. For the treatment of cerebral edema commonly used diuretic is furosemide at a dose of 0.7 mg/kg body weight after osmotic medication (according to the researchers, the effect of osmotic medication is then enhanced). [1]

Barbiturates:

In refractory cases of cerebral edema, where other interventions have proven ineffective, barbiturates like pentobarbital may be used. These agents induce a state of burst suppression on the electroencephalogram, reducing cerebral metabolic rate and intracranial pressure. However, the use of barbiturates is associated with significant side effects and necessitates careful monitoring. However, a meta-analysis of the available data from the literature showed that the use of barbiturates does not affect the condition and prognosis of cerebral edema.[1]

Propofol:

Propofol, a sedative commonly used in intensive care units and for managing elevated intracranial pressure (ICP), is cautioned against in traumatic brain injury (TBI) cases by the Brain Trauma Foundation. Its clinical benefits in reducing ICP, similar to barbiturates, are not well-established. Proposed mechanisms involve reducing cerebral metabolic rate and cerebral blood volume. Evidence suggests propofol may directly affect cerebral edema by modulating

aquaporin-4, potentially reducing neuroinflammatory responses. Despite its clinical use as second-line therapy for elevated intracranial pressure, limited human studies exist on propofol's efficacy in managing cerebral edema. Notably, propofol infusions, especially in younger patients at higher doses, carry risks of propofol infusion syndrome, metabolic acidosis, rhabdomyolysis, cardiac dysfunction, and hypertriglyceridemia, which can be fatal. [3]

The management of cerebral edema resulting from brain cancers, inflammation, and head injuries requires a multifaceted approach. In addition to the general therapeutic strategies outlined earlier, specific interventions tailored to the underlying cause are crucial [20]:

Brain Cancers: Treatment may involve a combination of surgical resection, radiation therapy, and chemotherapy. Corticosteroids, such as dexamethasone, are often utilized to reduce edema and alleviate symptoms. [1,18]

Inflammation: Immunosuppressive therapies, such as corticosteroids or other disease-modifying agents, may be employed to mitigate inflammatory responses and reduce cerebral edema. [10]

Head Injuries: Management includes measures to control intracranial pressure, surgical interventions if necessary, and rehabilitation to address neurological deficits.

It is crucial for healthcare professionals to carefully assess the patient's clinical condition and tailor the pharmacological treatment approach based on the specific etiology and severity of cerebral edema. Close monitoring and adjustments to the treatment plan may be required to optimize therapeutic outcomes while minimizing potential adverse effects. [5]

ANESTHESIOLOGICAL CONSIDERATIONS

Managing patients with cerebral edema, whether preoperatively or during surgery, requires careful consideration of anesthesiological factors to optimize outcomes. Key anesthesiological challenges include:

Intracranial Pressure (ICP) Monitoring: In cases of cerebral edema, especially those associated with brain tumors or head injuries, monitoring ICP becomes crucial during anesthesia. Anesthetic agents and interventions should be chosen to maintain ICP within acceptable limits. [5]

Choice of Anesthetic Agents: Anesthetic agents are part of the medical management of elevated intracerebral pressure. Although not directly affecting cerebral edema, pharmacologically induced coma lowers intracerebral pressure by lowering the cerebral metabolic demand of neurons and thus lowering the intracranial arterial volume. [3] Anesthesiologists must select agents that provide adequate anesthesia while minimizing the risk of exacerbating cerebral edema. Inhalational agents like isoflurane or intravenous agents like propofol are commonly used with caution. [7]

Maintenance of Cerebral Perfusion: Ensuring adequate cerebral perfusion pressure is essential to prevent ischemia. Anesthesiologists must balance factors such as blood pressure, carbon dioxide levels, and oxygenation to maintain optimal cerebral blood flow. [7]

Fluid Management: Careful fluid management is crucial, as excessive fluid administration can contribute to cerebral edema. Anesthesiologists need to tailor fluid therapy to the patient's specific condition, taking into account factors such as osmolality and colloid osmotic pressure. [7,20]

Temperature Control: Hypothermia may be induced during some surgical procedures to mitigate the risk of cerebral edema, especially in cases of brain injury. Anesthesiologists play a vital role in monitoring and maintaining appropriate patient temperatures. [5]

Emergence from Anesthesia: The emergence phase requires special attention, as fluctuations in blood pressure, carbon dioxide levels, and other factors can impact intracranial dynamics. A smooth transition from anesthesia is essential to avoid abrupt changes in cerebral perfusion. [5,7]

Collaboration with Neurosurgical Team: Effective communication and collaboration between anesthesiologists and the neurosurgical team are paramount. The anesthesiologist must be aware of the specific surgical goals, potential challenges, and the overall plan for managing cerebral edema during and after the procedure.

CONCLUSION

Understanding the intricate mechanisms contributing to cerebral edema is essential for tailoring effective medical interventions and improving patient rehabilitation. Recognition of clinical manifestations, ranging from cognitive changes to focal neurological deficits, is crucial for prompt medical evaluation and intervention. Anesthesiological considerations are paramount in the management of patients with cerebral edema, requiring careful monitoring

of intracranial pressure, careful selection of anesthetic agents, maintenance of cerebral perfusion, fluid management, temperature control, and collaboration with the neurosurgical team. The challenges posed by cerebral edema demand a multidisciplinary approach to ensure optimal patient care and outcomes. Ongoing research and collaboration within the medical community are crucial to enhance our understanding further and refine therapeutic approaches for this life-threatening condition. It should be emphasized that the recommendations in this review are based on available medical literature, which may not reflect all aspects of clinical expertise and practical experience.

Statement of the authors' contribution

Conceptualization: Maciej Świercz, Szymon Markowiak, Marta Wardęszkiewicz, Wiktoria Jabłońska, Amelia Kasprzak, Aleksandra Mańkowska, Monika Truchta, Agata Kolano, Anna Pejas

Methodology: Maciej Świercz, Szymon Markowiak, Marta Wardęszkiewicz, Wiktoria Jabłońska, Amelia Kasprzak, Aleksandra Mańkowska, Monika Truchta, Agata Kolano, Anna Pejas

Software: Maciej Świercz, Szymon Markowiak, Marta Wardęszkiewicz, Wiktoria Jabłońska, Amelia Kasprzak, Aleksandra Mańkowska, Monika Truchta, Agata Kolano, Anna Pejas

check: Szymon Markowiak, Marta Wardęszkiewicz, Wiktoria Jabłońska, Amelia Kasprzak, Maciej Świercz, Aleksandra Mańkowska, Monika Truchta, Agata Kolano, Anna Pejas

formal analysis: Maciej Świercz, Szymon Markowiak, Marta Wardęszkiewicz, Wiktoria Jabłońska, Amelia Kasprzak, Aleksandra Mańkowska, Monika Truchta, Agata Kolano, Anna Pejas

investigation: Maciej Świercz, Szymon Markowiak, Marta Wardęszkiewicz, Wiktoria Jabłońska, Amelia Kasprzak, Aleksandra Mańkowska, Monika Truchta, Agata Kolano, Anna Pejas

resources, data curation: Maciej Świercz, Szymon Markowiak, Marta Wardęszkiewicz, Wiktoria Jabłońska, Amelia Kasprzak, Aleksandra Mańkowska, Monika Truchta, Agata Kolano, Anna Pejas

writing - rough preparation: Maciej Świercz, Szymon Markowiak, Marta Wardęszkiewicz, Wiktoria Jabłońska, Amelia Kasprzak, Aleksandra Mańkowska, Monika Truchta, Agata Kolano, Anna Pejas

writing - review and editing: Maciej Świercz, Szymon Markowiak, Marta Wardęszkiewicz, Wiktoria Jabłońska, Amelia Kasprzak, Aleksandra Mańkowska, Monika Truchta, Agata Kolano, Anna Pejas

visualization: Maciej Świercz, Szymon Markowiak, Marta Wardęszkiewicz, Wiktoria Jabłońska, Amelia Kasprzak, Aleksandra Mańkowska, Monika Truchta, Agata Kolano, Anna Pejas

supervision: Maciej Świercz, Szymon Markowiak, Marta Wardęszkiewicz, Wiktoria Jabłońska, Amelia Kasprzak, Aleksandra Mańkowska, Monika Truchta, Agata Kolano, Anna Pejas

project administration: Maciej Świercz, Szymon Markowiak, Marta Wardęszkiewicz, Wiktoria Jabłońska, Amelia Kasprzak, Aleksandra Mańkowska, Monika Truchta, Agata Kolano, Anna Pejas

All authors have read and agreed with the published version of the manuscript.

Funding Statement

The study did not receive special funding.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Conflict of Interest Statement

No conflict of interest.

REFERENCES

1. Łebkowski, W. J., Zajkowska, J., Czupryna, P. (2014). Treatment of cerebral edema. *Leczenie obrzęku mózgu. Neurologia po Dyplomie*, 9(6), 49-52.

2. Stokum JA, Gerzanich V, Simard JM. Molecular pathophysiology of cerebral edema. *J Cereb Blood Flow Metab.* 2016 Mar;36(3):513-38. doi: 10.1177/0271678X15617172. Epub 2015 Nov 16. PMID: 26661240; PMCID: PMC4776312.
3. Halstead MR, Geocadin RG. The Medical Management of Cerebral Edema: Past, Present, and Future Therapies. *Neurotherapeutics.* 2019 Oct;16(4):1133-1148. doi: 10.1007/s13311-019-00779-4. PMID: 31512062; PMCID: PMC6985348.
4. Jha RM, Kochanek PM, Simard JM. Pathophysiology and treatment of cerebral edema in traumatic brain injury. *Neuropharmacology.* 2019 Feb;145(Pt B):230-246. doi: 10.1016/j.neuropharm.2018.08.004. Epub 2018 Aug 4. PMID: 30086289; PMCID: PMC6309515.
5. Zusman BE, Kochanek PM, Jha RM. Cerebral Edema in Traumatic Brain Injury: a Historical Framework for Current Therapy. *Curr Treat Options Neurol.* 2020 Mar;22(3):9. doi: 10.1007/s11940-020-0614-x. Epub 2020 Mar 3. PMID: 34177248; PMCID: PMC8223756.
6. Jha RM, Kochanek PM. A Precision Medicine Approach to Cerebral Edema and Intracranial Hypertension after Severe Traumatic Brain Injury: Quo Vadis? *Curr Neurol Neurosci Rep.* 2018 Nov 7;18(12):105. doi: 10.1007/s11910-018-0912-9. PMID: 30406315; PMCID: PMC6589108.
7. Tonković D, Bandić Pavlović D, Baronica R, Virag I, Miklić Bubić M, Kovač N, Željko D. REGIONAL ANESTHESIA FOR NEUROSURGERY. *Acta Clin Croat.* 2019 Jun;58(Suppl 1):48-52. doi: 10.20471/acc.2019.58.s1.07. PMID: 31741559; PMCID: PMC6813468.
8. Gu Y, Zhou C, Piao Z, Yuan H, Jiang H, Wei H, Zhou Y, Nan G, Ji X. Cerebral edema after ischemic stroke: Pathophysiology and underlying mechanisms. *Front Neurosci.* 2022 Aug 18;16:988283. doi: 10.3389/fnins.2022.988283. PMID: 36061592; PMCID: PMC9434007.
9. Magid-Bernstein J, Girard R, Polster S, Srinath A, Romanos S, Awad IA, Sansing LH. Cerebral Hemorrhage: Pathophysiology, Treatment, and Future Directions. *Circ Res.* 2022 Apr 15;130(8):1204-1229. doi: 10.1161/CIRCRESAHA.121.319949. Epub 2022 Apr 14. PMID: 35420918; PMCID: PMC10032582.
10. Jurcau A, Simion A. Neuroinflammation in Cerebral Ischemia and Ischemia/Reperfusion Injuries: From Pathophysiology to Therapeutic Strategies. *Int J Mol Sci.* 2021 Dec 21;23(1):14. doi: 10.3390/ijms23010014. PMID: 35008440; PMCID: PMC8744548.

- 11.** Jha RM, Raikwar SP, Mihaljevic S, Casabella AM, Catapano JS, Rani A, Desai S, Gerzanich V, Simard JM. Emerging therapeutic targets for cerebral edema. *Expert Opin Ther Targets*. 2021 Nov;25(11):917-938. doi: 10.1080/14728222.2021.2010045. Epub 2022 Jan 2. PMID: 34844502; PMCID: PMC9196113.
- 12.** Hackett PH, Yarnell PR, Weiland DA, Reynard KB. Acute and Evolving MRI of High-Altitude Cerebral Edema: Microbleeds, Edema, and Pathophysiology. *AJNR Am J Neuroradiol*. 2019 Mar;40(3):464-469. doi: 10.3174/ajnr.A5897. Epub 2019 Jan 24. PMID: 30679208; PMCID: PMC7028681.
- 13.** Kitchen P, Salman MM, Halsey AM, Clarke-Bland C, MacDonald JA, Ishida H, Vogel HJ, Almutiri S, Logan A, Kreida S, Al-Jubair T, Winkel Missel J, Gourdon P, Törnroth-Horsefield S, Conner MT, Ahmed Z, Conner AC, Bill RM. Targeting Aquaporin-4 Subcellular Localization to Treat Central Nervous System Edema. *Cell*. 2020 May 14;181(4):784-799.e19. doi: 10.1016/j.cell.2020.03.037. PMID: 32413299; PMCID: PMC7242911.
- 14.** Sulhan S, Lyon KA, Shapiro LA, Huang JH. Neuroinflammation and blood-brain barrier disruption following traumatic brain injury: Pathophysiology and potential therapeutic targets. *J Neurosci Res*. 2020 Jan;98(1):19-28. doi: 10.1002/jnr.24331. Epub 2018 Sep 27. PMID: 30259550; PMCID: PMC6437022.
- 15.** Cash A, Theus MH. Mechanisms of Blood-Brain Barrier Dysfunction in Traumatic Brain Injury. *Int J Mol Sci*. 2020 May 8;21(9):3344. doi: 10.3390/ijms21093344. PMID: 32397302; PMCID: PMC7246537.
- 16.** Wan Y, Holste KG, Hua Y, Keep RF, Xi G. Brain edema formation and therapy after intracerebral hemorrhage. *Neurobiol Dis*. 2023 Jan;176:105948. doi: 10.1016/j.nbd.2022.105948. Epub 2022 Dec 5. PMID: 36481437; PMCID: PMC10013956.
- 17.** Cook AM, Morgan Jones G, Hawryluk GWJ, Mailloux P, McLaughlin D, Papangelou A, Samuel S, Tokumaru S, Venkatasubramanian C, Zacko C, Zimmermann LL, Hirsch K, Shutter L. Guidelines for the Acute Treatment of Cerebral Edema in Neurocritical Care Patients. *Neurocrit Care*. 2020 Jun;32(3):647-666. doi: 10.1007/s12028-020-00959-7. PMID: 32227294; PMCID: PMC7272487.
- 18.** Stokum JA, Gerzanich V, Sheth KN, Kimberly WT, Simard JM. Emerging Pharmacological Treatments for Cerebral Edema: Evidence from Clinical Studies. *Annu Rev Pharmacol Toxicol*. 2020 Jan 6;60:291-309. doi: 10.1146/annurev-pharmtox-010919-023429. PMID: 31914899; PMCID: PMC7122796.

- 19.** Robert SM, Reeves BC, Alper SL, Zhang J, Kahle KT. New drugs on the horizon for cerebral edema: what's in the clinical development pipeline? *Expert Opin Investig Drugs*. 2020 Oct;29(10):1099-1105. doi: 10.1080/13543784.2020.1813715. Epub 2020 Sep 20. PMID: 32815401; PMCID: PMC8104020.
- 20.** Dąbrowski W, Woodcock T, Rzecki Z, Malbrain MLNG. The use of crystalloids in traumatic brain injury. *Anaesthesiol Intensive Ther*. 2018;50(2):150-159. doi: 10.5603/AIT.a2017.0067. Epub 2017 Nov 22. PMID: 29165777.
- 21.** Ohmura K, Tomita H, Hara A. Peritumoral Edema in Gliomas: A Review of Mechanisms and Management. *Biomedicines*. 2023 Oct 9;11(10):2731. doi: 10.3390/biomedicines11102731. PMID: 37893105; PMCID: PMC10604286.